Research programme: neuraminidase inhibitors - Aviragen Therapeutics/Daiichi Sankyo

Drug Profile

Research programme: neuraminidase inhibitors - Aviragen Therapeutics/Daiichi Sankyo

Alternative Names: BTA929; BTA938; BTA978

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Daiichi Sankyo Company
  • Class Guanidines
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
  • 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
  • 20 Jan 2011 Preclinical development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top